Seagen Dividenda 2024

Co dělá Seagen?

Seagen Inc is a pharmaceutical and biotech company specialized in the development of drugs for cancer treatment and supporting the health of patients with chronic diseases. The company was founded in 1997 and has its headquarters in Bothell, Washington. Seagen Inc's history began when the founders, Clay Siegall and H. Perry Fell, decided to establish a company focused on developing innovative technologies and biological solutions for fighting cancer. The company started with a small workforce and a focus on the development of antibodies against cancer cells. Over the years, Seagen has become a major player in the industry and has launched several successful drugs worldwide. Seagen Inc specializes in the development of cancer medications, including antibodies against cancer cells. The company strives to improve the effectiveness of cancer treatments and reduce the number of side effects. Its flagship products are Adcetris and Padcev, both used for the treatment of specific types of cancer. Adcetris (Brentuximab Vedotin) is an antibody-drug conjugate and the first of its kind approved worldwide for use against Hodgkin lymphomas and systemic anaplastic large cell lymphoma. It contains a special chemical that is bound to an antibody to directly attack cancer cells. Adcetris has proven to be very effective against lymphomas and is available on prescription in many countries. Padcev (Enfortumab Vedotin-ejfv) is another antibody-drug conjugate used for the treatment of bladder cancer. The drug has shown effectiveness in clinical studies and has been approved by the FDA to help patients who have no other treatment options. Padcev is being developed and marketed by Seagen in collaboration with Astellas Pharma. In addition to developing cancer medications, Seagen Inc is also involved in the research and development of technologies for autoimmune disease therapy. The company has developed a technology platform that has proven to be highly effective in the development of antibody-based therapies. This platform is used both internally and in partnerships with other pharmaceutical companies. Seagen Inc also leverages partnerships to expand its business globally and advance the development of new therapies. The company has entered into a strategic partnership with Takeda Pharmaceutical to support the development and commercialization of Adcetris. Additionally, Seagen Inc collaborates with various universities and research institutions to develop new technologies and treatment options. Overall, Seagen Inc has experienced strong growth in recent years and has become a major player in the biotech and pharmaceutical industry. The company remains committed to its mission of developing innovative technologies and solutions for fighting cancer and other chronic diseases. Seagen je jednou z nejoblíbenějších společností na Eulerpool.com.